ResMed

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024

Retrieved on: 
Thursday, April 25, 2024
Somnolence, CHESS, ResMed, Webcast, Software as a service, CDI, PAP, Australian Securities Exchange, Sleep, Growth, F40, Video game

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024.

Key Points: 
  • Revenue in Europe, Asia, and other markets, excluding Software-as-a-Service, grew by 3 percent on a constant currency basis.
  • SG&A expenses improved to 19.2 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 8, 2024, through May 9, 2024, inclusive.
  • ResMed will discuss its third quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

Retrieved on: 
Thursday, April 4, 2024
ResMed, Webcast

Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

Key Points: 
  • Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
  • A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast.
  • In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 25, 2024, until May 9, 2024, at:

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

Retrieved on: 
Friday, March 15, 2024
Health, Sleep apnea, Conditional sentence, Obesity, Exercise, RMD, ResMed, Somnolence, SAN, Insomnia, Social media, Sleep, ASX, News, Female, Irritation, Woman, Periodic breathing, COPD, Nursing

More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.

Key Points: 
  • More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.
  • SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.
  • To learn more about ResMed’s 2024 Global Sleep Survey or for help identifying if you have symptoms that could indicate poor sleep health, visit https://www.resmed.com/sleepassessment .
  • The 2024 ResMed Global Sleep Survey included a total of 36,000 respondents across 17 markets including Australia, Brazil, China, France, Germany, Hong Kong, India, Ireland, Japan, Korea, Mexico, New Zealand, Singapore, Taiwan, Thailand, UK and USA, between December 2023 and January 2024.

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on: 
Friday, March 15, 2024
Diagnosis, ResMed, Non-invasive ventilation, Sleep apnea, CPAP, Growth, Prevalence, APAP, LivaNova, Obstructive sleep apnea, Polysomnography, Ageing, Ventilation, Research, Overalls, Central sleep apnea, Woman, Hub, Interest, USD, Administration, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Retrieved on: 
Wednesday, March 6, 2024
RMD, SAN, CPAP, Sleep apnea, Sleep, ResMed, ASX, F40, Patient, Claustrophobia, Trial of the century, Mask, COPD, Cosmetics

Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.

Key Points: 
  • Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.
  • The AirFit F40 addresses this problem by providing the necessary pressure support in a more comfortable, lower-profile full-face mask.
  • The mask is ideal for people who sleep on their side, are claustrophobic, and want the stability and seal of a universal fit mask in a minimalist design.
  • AirFit F40 masks are available in the U.S., with plans to launch in Canada, followed by EMEA, Latin America, and APAC.

Synthpop unveils new possibilities for AI at the biggest DME gathering in the industry - MedTrade 2024

Retrieved on: 
Tuesday, February 20, 2024
Multimedia, API, HME, Innovation system, Itamar Medical, ResMed, Genetic testing, Health, DME, Electronic health record, Workflow

DALLAS, Feb. 20, 2024 /PRNewswire/ -- Synthpop will debut its cutting-edge AI solutions at MedTrade, the largest HME and DME gathering in the industry, March 26-28 2024.

Key Points: 
  • DALLAS, Feb. 20, 2024 /PRNewswire/ -- Synthpop will debut its cutting-edge AI solutions at MedTrade, the largest HME and DME gathering in the industry, March 26-28 2024.
  • Synthpop places an emphasis on connecting with other professionals at MedTrade to discuss advancements in AI that improve patient care while reducing administrative and clinical burnout.
  • *
    Synthpop has experienced early success as a healthcare startup, with customers in HME/DME, Sleep Medicine, Wound Care, and Genetic Testing.
  • "This trade show is a testament to our commitment to revolutionizing the DME industry with our innovative AI solutions .

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Thursday, February 15, 2024
Marketing, Senior, Indiana University, INC, Doctor of Philosophy, LOS, Corporate communication, NIRI, MD, SLRN, Bank, Life Technologies, Kellogg School, ResMed, ASX, Salomon Brothers, Strategic planning, Patient, Thermo Fisher Scientific, Northwestern University, Management

LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications.
  • Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.
  • Ms. Lee began her investor relations career at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
  • “I am honored to join ACELYRIN to lead the investor relations and corporate communications functions as we progress on our corporate journey in support of patients,” said Ms. Lee.

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Retrieved on: 
Monday, February 12, 2024
RMD, SAN, Inhalation, Central sleep apnea, ASV, MyAir, CPAP, Sleep apnea, Culture, Part, Sleep, Obstructive sleep apnea, Exhalation, Respiratory rate, Digital technology, ResMed, ASX, IPAP, PAP, Patient, Ventilation, Software, Pressure, Medical device

AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.

Key Points: 
  • AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.
  • This design allows the device to align more closely with the patient’s natural breathing pattern.
  • myAir3, a patient engagement app that tracks sleep and therapy progress with a daily sleep score, now with support for bilevel patients.
  • AirView, a secure, cloud-based system that helps providers monitor and manage patients’ therapy remotely, enabling an informed pathway to optimal care.

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Retrieved on: 
Tuesday, February 6, 2024
CARE, Policy, AHI, Life, Splint (medicine), Nausea, Myotherapy, UnitedHealth Group, Irritation, Obstructive sleep apnea, Sleep, Nose, Patient, Safety, ResMed, FDA, CPAP, Respironics, PAP, Skin, Food, Mars, Therapy, Vomiting, Dizziness, Continuous positive airway pressure, Death, Headache, Health, Asthma, Pharmaceutical industry

In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.

Key Points: 
  • In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.
  • Vivos-trained providers currently treat failed HGNS cases using Vivos CARE oral medical devices and treatment plans.
  • Vivos believes most OSA patients seeking HGNS implants have high-moderate or severe OSA, leaving Vivos CARE oral medical devices as their only approved oral appliance therapy option.
  • We believe all of these factors create very significant revenue opportunities for us as we continue to spread the word about our product offerings.”

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
Wednesday, January 24, 2024
DAN, Woman, ResMed, Patient, Wind, Software as a service, Magnet, American Medical Association, COPD, JAMA, Investment, CDI, Journal, Acquisition, Chronic obstructive pulmonary disease, Webcast, Retirement, Australian Securities Exchange, CHESS, Mask, Growth

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023.

Key Points: 
  • Gross margin decreased by 50 basis points mainly due to costs associated with a field safety notification for masks with magnets.
  • SG&A expenses improved to 19.1 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
  • ResMed will discuss its second quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.